Literature DB >> 23217693

Treatment of neurally mediated reflex syncope.

Juan C Guzman1, Luciana V Armaganijan, Carlos A Morillo.   

Abstract

Neurally mediated reflex syncope, more commonly known as vasovagal syncope (VVS), remains the most common cause of transient loss of consciousness and syncope in all age groups. Most evidence assessing treatment of VVS derived from randomized clinical trials is limited. Multiple modalities of both nonpharmacologic and pharmacologic strategies have been tested, with conflicting results. The treatment of VVS has been directed toward interventions that interrupt the reflex response at different levels, hypothetically preventing the onset of syncope. This article reviews the available evidence of the different nonpharmacologic and pharmacologic therapies available for the treatment of recurrent VVS.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23217693     DOI: 10.1016/j.ccl.2012.10.007

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  2 in total

1.  Alteration of gene expression profiling including GPR174 and GNG2 is associated with vasovagal syncope.

Authors:  Yu-Juan Huang; Zai-wei Zhou; Miao Xu; Qing-wen Ma; Jing-bin Yan; Jian-yi Wang; Quo-qin Zhang; Min Huang; Liming Bao
Journal:  Pediatr Cardiol       Date:  2014-11-01       Impact factor: 1.655

2.  [Syncope from the viewpoint of a neurologist].

Authors:  A Bickel; J Röther
Journal:  Herz       Date:  2014-06       Impact factor: 1.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.